WANG Mengxing, PAN Yuesong, LIU Dandan, JIN Aoming. Considerations for Clinical Trial Negative Results
[J]. Chinese Journal of Stroke, 2023, 18(06): 645-650.
[1]HOPEWELL S,LOUDON K,CLARKE M J,et al. Publication bias in clinical trials due to statistical significance or direction of trial results[J/OL]. Cochrane Database Syst Rev,2009,2009(1):MR000006[2022-08-11]. https://doi.org/10.1002/14651858.MR000006.pub3.
[2]ClinicalTrials. gov[EB/OL]. (2023-05-26)[ 2023-05-26]. https://www.clinicaltrials.gov/ct2/resources/trends#RegisteredStudiesOverTime.
[3]ANNIE S,ANDY B. China Clinical Trials Landscape[EB/OL]. (2021-09-03)[ 2023-04-30]. https://pharmaintelligence.informa.com/resources/product-content/clinical-trials-landscape.
[4]WOLFE C D,SMEETON N C,COSHALL C,et al. Survival differences after stroke in a multiethnic population:follow-up study with the South London stroke register[J]. BMJ,2005,331(7524):431.
[5]POCOCK S J,STONE G W. The primary outcome fails - what next?[J]. N Engl J Med,2016,375(9):861-870.
[6]SWEDBERG K,KOMAJDA M,BÖHM M,et al. Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study[J]. Lancet,2010,376(9744):875-885.
[7]BHATT D L,STONE G W,MAHAFFEY K W,et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events[J]. N Engl J Med,2013,368(14):1303-1313.
[8]COHN J N,PFEFFER M A,ROULEAU J,et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure(MOXCON)[J]. Eur J Heart Fail,2003,5(5):659-667.
[9]DI MAIO M,AUDISIO M,CARDONE C,et al. The use of not-negative conclusions to describe results of formally negative trials presented at oncology meetings[J]. JAMA Oncol,2020,6(6):926-927.
[10]国家药品监督管理局. GGTG-2016-11712 药物临床试验数据管理与统计分析的计划和报告指导原则[S]. 北京:中国标准出版社,2016.
[11]国家药品监督管理局,国家卫生健康委员会. FGWJ-2020-10001 药物临床试验质量管理规范[S]. 北京:中国标准出版社,2020.
[12]Food and Drug Administration. Guidance recap podcast multiple endpoints in clinical trials[EB/OL]. (2022-10-20)[ 2023-05-26]. https://wwwfdagov/drugs/guidances-drugs/guidance-recap-podcast-multiple-endpoints-clinical-trials.
[13]European Medicines Agency. EMA/744060/2017 ICH Topic E 9 Statistical Principles for Clinical Trials[S]. 1998.
[14]SUN X,BRIEL M,BUSSE J W,et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials:systematic review[J/OL]. BMJ,2011,342:d1569[2023-04-30]. https://doi.org/10.1136/bmj.d1569.
[15]POCOCK S J,STONE G W. The primary outcome is positive - is that good enough?[J]. N Engl J Med,2016,375(10):971-979.
[16]ASSMANN S F,POCOCK S J,ENOS L E,et al. Subgroup analysis and other(mis)uses of baseline data in clinical trials[J]. Lancet,2000,355(9209):1064-1069.
[17]ROGERS J K,POCOCK S J,MCMURRAY J J,et al. Analysing recurrent hospitalizations in heart failure:a review of statistical methodology,with application to CHARM-Preserved[J]. Eur J Heart Fail,2014,16(1):33-40.
[18]NEAD K T,WEHNER M R,MITRA N. The use of "trend" statements to describe statistically nonsignificant results in the oncology literature[J]. JAMA Oncol,2018,4(12):1778-1779.
[19]MACAYA F,RYAN N,SALINAS P,et al. Challenges in the design and interpretation of noninferiority trials:insights from recent stent trials[J]. J Am Coll Cardiol,2017,70(7):894-903.
[20]POCOCK S J,ROSSELLO X,OWEN R,et al. Primary and secondary outcome reporting in randomized trials:JACC state-of-the-art review[J]. J Am Coll Cardiol,2021,78(8):827-839.
[21]WIESCHOWSKI S,CHIN W W L,FEDERICO C,et al. Preclinical efficacy studies in investigator brochures:do they enable risk-benefit assessment?[J/OL]. PLoS Biol,2018,16(4):e2004879[2023-04-30]. https://doi.org/10.1371/journal.pbio.2004879.
[22]YASINSKI E. Study questions animal data underlying many clinical trials[EB/OL]. (2018-04-05)[ 2023-04-30]. https://www.sciencemag.org/news/2018/04/clinical-trials-may-be-based-flimsy-animal-data.
[23]PAN Y S,MENG X,YUAN B S,et al. Indobufen versus aspirin in patients with acute ischaemic stroke in China(INSURE):a randomised,double-blind,double-dummy,active control,non-inferiority trial[J]. Lancet Neurol,2023,22(6):485-493. .
[24]MOHR F W,MORICE M C,KAPPETEIN A P,et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease:5-year follow-up of the randomised,clinical SYNTAX trial[J]. Lancet,2013,381(9867):629-638.
[25]STONE G W,SABIK J F,SERRUYS P W,et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease[J]. N Engl J Med,2016,375(23):2223-2235.
[26]LEE J Y,SUNG K C,CHOI H I. Comparison of aspirin and indobufen in healthy volunteers[J]. Platelets,2016,27(2):105-109.
[27]WU H Y,XU L L,ZHAO X,et al. Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation(OPTION):a randomized,open-label,end point-blinded,noninferiority trial[J]. Circulation,2023,147(3):212–222.